Lupin announced today that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental New Drug Application (sNDA) to expand the use of Solosec (secnidazole) to include the treatment of trichomoniasis in adults.
SOLOSEC demonstrated a 92.2 per cent clinically and statistically significant cure rate for patients with trichomoniasis based on a landmark Phase 3 clinical trial.
Lupin Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted their supplemental New Drug Application (sNDA) for Solosec® (secnidazole) for the treatment of trichomoniasis in adults and adolescents.